Premium
Cholesterol lowering effect of the recombinant α'E peptide from 7S soy globulin in cholesterol‐fed rats upon chronic treatment
Author(s) -
Lovati Maria Rosa,
Manzoni Cristina,
Parolari Anna,
Castiglioni Silvia,
Morazzoni Paolo,
Duranti Marcello
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.224.2
Subject(s) - endocrinology , medicine , clofibrate , chemistry , cholesterol , recombinant dna , peptide , in vivo , ldl receptor , globulin , very low density lipoprotein , hyperlipidemia , lipoprotein , biochemistry , biology , gene , microbiology and biotechnology , diabetes mellitus
Aim of the study was to evaluate the effect of a chronic oral administration of the recombinant α'E peptide from 7S soy globulin, previously shown to up‐regulate the LDL‐R in vitro, in male Sprague‐Dawley rats fed on cholesterol‐rich (HC) diet. α'E peptide (25 and 50 mg/Kg b.w/d) was administered to rats for 21 days; the results were compared with that obtained in rats treated either with 7S‐α'rich (20 mg/Kg b.w./d) or clofibrate (200 mg/kg b.w./d). α'E peptide markedly decreased plasma cholesterol (C) and triglycerides (TG) (25 mg/Kg/d: −26 and −23 %, respectively; 50 mg/Kg/d: −29 and −13%, respectively). Similar results were obtained in 7S‐α'rich‐treated rats (−27 and −34%, respectively). Ten‐fold amounts clofibrate reduced C and TG by 32 and 35%, respectively. The highest dose of α'E peptide increased (+62%) liver β‐VLDL‐R expression versus values of HC group, thus restoring the receptor activity to that of 7S‐α'rich‐treated rats or of rats fed on standard diet. This is the first in vivo evidence of potential activity of the recombinant α'E peptide from 7S soy globulin on plasma lipid homeostasis. Supported by a grant from MIUR of Italy